Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 55.50.
Forward PE Ratio (55.50) = Close Price ($152.55) / Consensus Forward EPS ($2.75)
FORWARD PE RATIO
55.50
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
+178.68%
vs the sector median at left
Merck & Co., Inc.
Market Cap
$376.77B
Forward PE Ratio
55.50
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Merck & Co., Inc. (MRK) | $376.77B | 55.50 |
| UnitedHealth Group Incorporated (UNH)vs › | $354.28B | 19.79 |
| AbbVie Inc. (ABBV)vs › | $468.22B | 18.88 |
| AstraZeneca PLC (AZN)vs › | $257.41B | 16.21 |
| Amgen Inc. (AMGN)vs › | $237.11B | 19.04 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $233.85B | 25.06 |
| Novo Nordisk A/S (NVO)vs › | $207.55B | N/A |
| Abbott Laboratories (ABT)vs › | $201.83B | 21.14 |
| Gilead Sciences, Inc. (GILD)vs › | $181.42B | N/A |
| Pfizer Inc. (PFE)vs › | $159.98B | 9.44 |
Trailing P/E
122.0
reported TTM EPS
Forward P/E
55.5
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.75 implies +120.0% EPS growth vs the reported trailing $1.25.
At today's $152.55 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.75 | $2.52 – $4.19 | 14 | 55.5x |
| 2027-12-31 | $9.54 | $9.09 – $9.91 | 14 | 16.0x |
| 2028-12-31 | $10.53 | $8.71 – $12.64 | 8 | 14.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute